He holds a PhD in Pharmacy from the University of Copenhagen, Denmark, with extensive experience in research and development of vaccine delivery systems and immunological adjuvants.
He has over 20 years of experience at the interface of pharmacology and immunology applied to vaccine development, with a focus on adjuvant systems and targeted antigen delivery technologies.
He leads the development and expansion of innovative vaccine delivery systems and immunostimulatory adjuvants, including combined adjuvant formulations.
He played a key role in the development of the CAF® (Combined Adjuvant Formulation) family of adjuvants, originally developed at the Statens Serum Institut, including CAF®01 and CAF®09b, now being advanced as commercial products by Croda Pharma.
He is recognized as an international expert in vaccine adjuvant research, with extensive experience in global vaccine R&D programs.
In addition to his role at Croda Pharma, he is an Adjunct Research Professor at the Statens Serum Institut, Denmark.
He currently serves as Global Head of Research and Development for Adjuvant Systems at Croda Pharma.
